Malaria Clinical Trial
Official title:
Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
The purpose of the study is to determine the safety and tolerability of ID administration of PfSPZ Challenge to volunteers taking chloroquine chemoprophylaxis (an approach called PfSPZ-CVac).
The study is a single centre, double blind, randomized controlled clinical trial.
Volunteers, investigators and laboratory personnel will be blinded.
A maximum of 30 volunteers will be randomly divided into four groups. All volunteers will
receive standard weekly chloroquine chemoprophylaxis for a period of 14 weeks (98 days).
During this period, groups 1 and 3 will receive six ID injections of PfSPZ Challenge,
containing a total of 75,000 PfSPZ of the Pf NF54 strain, on days 8, 36 and 64
(immunizations 1, 2 and 3). The control groups 2 and 4 will receive ID injections with
normal saline (NS) on the same days.
Thirty-three days after the last dose of chloroquine, volunteers in groups 1 and 2 will have
controlled human malaria infection (CHMI) by the bites of five mosquitoes infected with
PfSPZ of the Pf NF54 strain. If ≥75% of volunteers in group 1 are protected against this
homologous Pf CHMI, volunteers in groups 3 and 4 will have CHMI by the bites of five
mosquitoes infected with the heterologous Pf NF135.C10 strain 75 days after the last dose of
chloroquine.
If <75% of volunteers in group 1 are protected against the homologous Pf CHMI, volunteers in
groups 3 and 4 will receive an additional immunization (immunization 4), which will consist
of six ID injections on the same day of 75,000 PfSPZ Challenge and NS respectively, at day
162. In this fourth immunization period chloroquine will be administered for another 6 weeks
starting at day 154. Finally, 33 days after the last dose of chloroquine, volunteers in
groups 3 and 4 will have homologous Pf CHMI by the bites of five PfSPZ-infected mosquitoes.
After CHMI all volunteers will be treated with a curative regimen of Malarone® (each tablet
containing 250 mg atovaquone and 100 mg proguanil), either at the time of detection of blood
stage parasitemia or 21 days after exposure to PfSPZ-infected mosquitoes. Volunteers will be
checked for parasites by thick smear at least twice after treatment.
If one of the volunteers is not fit to participate in the study on day -1, an alternate
volunteer who passed screening will replace him or her. For this purpose 3 additional
volunteers will be screened for possible back up.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |